3/6
08:33 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $6.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $6.00 to $7.00. They now have a "buy" rating on the stock.
3/6
08:12 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/6
02:16 am
ocgn
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs [Yahoo! Finance]
Medium
Report
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs [Yahoo! Finance]
3/5
01:27 pm
ocgn
Ocugen (OCGN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Ocugen (OCGN) Q4 2024 Earnings Call Transcript [Yahoo! Finance]
3/5
11:01 am
ocgn
https://seekingalpha.com/article/4764889-ocugen-inc-ocgn-q4-2024-earnings-call-transcript [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4764889-ocugen-inc-ocgn-q4-2024-earnings-call-transcript [Seeking Alpha]
3/5
07:42 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Medium
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/5
07:02 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
3/4
11:35 pm
ocgn
Here's the major earnings before the open tomorrow [Seeking Alpha]
Medium
Report
Here's the major earnings before the open tomorrow [Seeking Alpha]
3/3
09:53 am
ocgn
Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease [Yahoo! Finance]
Medium
Report
Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease [Yahoo! Finance]
3/3
09:00 am
ocgn
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
High
Report
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
2/27
08:46 am
ocgn
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Low
Report
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
2/21
09:42 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/21
08:00 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
2/13
08:53 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
2/13
08:10 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at HC Wainwright from $7.00 to $8.00. They now have a "buy" rating on the stock.
2/12
07:42 am
ocgn
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
2/3
07:12 am
ocgn
Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa [Yahoo! Finance]
Low
Report
Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa [Yahoo! Finance]
2/3
06:30 am
ocgn
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
Low
Report
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
1/31
04:26 pm
ocgn
Ocugen files to sell 57.54M shares of common stock for holders [Seeking Alpha]
Low
Report
Ocugen files to sell 57.54M shares of common stock for holders [Seeking Alpha]
1/27
06:30 am
ocgn
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Medium
Report
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
1/23
09:49 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
1/16
07:30 am
ocgn
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Low
Report
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
1/13
11:41 am
ocgn
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
1/13
06:30 am
ocgn
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Medium
Report
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
12/19
06:45 am
ocgn
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]